Company News: Pfizer

Share this article:
Pfizer CEO Jeff Kindler told shareholders that no one Pfizer product "is expected to account for more than 10% of our annual revenue, once Lipitor loses US exclusivity" late next year. Lipitor accounted for 23%, or $11 billion, of the company's annual revenue in 2009. Preliminary voting results on a handful of topics -- excluding stockholders from advising on executive pay, confirming the company's public accounting firm of record (KPMG), confirming company directors and a shrinking of the percent of shares required to hold special shareholder meetings were all passed by large margins. Only one initiative was rejected -- a proposal put forth by Evelyn Y. Davis -- that would have halted the practice of offering executives stock options. The annual shareholders meeting was held in Cleveland.
Share this article:
close

Next Article in Business Briefs

Email Newsletters

More in Business Briefs

Researchers hit links for charity

The PMR Charities Golf Classic teed up more than $20,000 for St. Jude Children's Research Hospital.

FDA to review Neupogen biosimilar

Novartis subsidiary Sandoz announced Thursday that the FDA has agreed to review its filgrastim biosimilar which is already approved in 40 countries.

FDA approves a new painkiller

Targiniq ER combines the prescription opioid oxycodone and naloxone, which is often used to treat overdoses.